- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Menetrier Disease: A Case Report (Crown Ballroom) - Sep 4, 2022 - Abstract #ACG2022ACG_3822;
Treatment of H. pylori , CMV, and medications like octreotide or cetuximab showed improvement in disease progression in some patients. Figure: Image 1: Marked enlarged gastric rugae on endoscopy (A) and foveolar hyperplasia on biopsy (B).
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
All Roads Lead to SMAD4: Menetrier’s Disease in Association With a SMAD4 Mutation (Crown Ballroom) - Sep 4, 2022 - Abstract #ACG2022ACG_861;
Medical therapies include Cetuximab and Octreotide but total gastrectomy remains the mainstay as a curative option...Despite lacking confirmatory genetic testing in our patient’s father, it is safe to assume the autosomal dominant SMAD4 mutation is the culprit in both individuals despite the differential expression as disease. Figure: Endoscopic and Pathologic appearance of Menetriers Disease associated with SMAD4
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Quantitative analysis of EGFR expression and distribution upon drug treatment in colorectal organoid models (Exhibition Hall) - Sep 3, 2022 - Abstract #AACRNCIEORTC2022AACR_NCI_EORTC_459;
Methods An established biobank of normal colon and colorectal cancer organoid models was characterized for its sensitivity to the growth factor EGF, EGFR-inhibitors (Cetuximab), and standard-of-care compounds...The outcome of this work demonstrated that organoids are versatile, multicellular structures that are highly suitable for studying the expression and redistribution of disease-relevant targets. No
- |||||||||| Exkivity (mobocertinib) / Takeda
Mechanisms of resistance to mobocertinib in EGFR exon 20 insertion-mutant non-small cell lung cancer (NSCLC) (Exhibition Hall) - Sep 3, 2022 - Abstract #AACRNCIEORTC2022AACR_NCI_EORTC_446;
Conclusions EGFR C797S mutation and EGFR amplification were identified as resistance mechanisms to mobocertinib in EGFR exon 20 insertion-mutant NSCLC models. Combined treatment of brigatinib plus cetuximab or amivantamab may be an effective therapeutic strategy for EGFR exon 20 insertion/C797S-mutant NSCLC in preclinical models.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Comparison of biomarker selection methods in high-dimensional genomic data (Exhibition Hall) - Sep 3, 2022 - Abstract #AACRNCIEORTC2022AACR_NCI_EORTC_409;
Therefore, selecting the best predictive composite biomarker in vitro screening for in vivo validation can significantly reduce costs and accelerate the early drug development process. No
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
Human EGFR (HER) family ligands as targets in Cancer and Autoimmune Disease (Exhibition Hall) - Sep 3, 2022 - Abstract #AACRNCIEORTC2022AACR_NCI_EORTC_215;
Biography Lasker Prize 2019 for trastuzumab .Background...Examples are methotrexate and cyclophosphamide which are used to treat many different malignancies as well as being first-line treatments for rheumatoid arthritis...The extension of anti-receptor antibodies from oncology to autoimmune disease has been slowed because of unwanted toxicity of reagents like gefitinib or cetuximab...The EGFR-Fc/HER3-Fcinstead acts as a ligand trap, which can remove excess growth factors from diseased tissues, thus starving diseased cells and preserving normal cell function. This principal can possibly be applied to both cancer and rheumatoid arthritis.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Pembrolizumab and Cetuximab as therapeutic options for ACC in head and neck (Pubmed Central) - Sep 3, 2022
Observed PK properties and AE profile support continued development in combination with other anti-cancer therapies, which continue to be investigated alongside additional intermittent dosing schedules. No abstract available
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, RSL3 / Stanford University
Journal: Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab. (Pubmed Central) - Sep 3, 2022
Excitingly, the ferroptosis-inducer RSL3 plays a synthetic role with EGFR monoclonal antibody Cetuximab to inhibit the survival of nasopharyngeal carcinoma cells (CNE-2), which are insensitive to both ferroptosis induction and EGFR inhibition due to a high level of FTH1 and a low level of EGFR, respectively. Our findings prove that FTH1 plays a vital role in ferroptosis resistance in HNSCCs and also provide clues to target HNSCCs resistant to ferroptosis induction and/or EGFR inhibition.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, IO biomarker: Genome-Wide Super-Enhancer-Based Analysis: Identification of Prognostic Genes in Oral Squamous Cell Carcinoma. (Pubmed Central) - Sep 3, 2022
The high and low expression groups of the four genes showed significant differences in prognosis, suggesting that there are clear differences in the pathways based on the underlying gene expression profiles. These data indicate that potential stratified therapeutic strategies could be used to overcome resistance to drugs (including cetuximab) and further improve responses in drug-sensitive patients.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
First and Second Line Treatment Patterns in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Chart Review Study in Three Countries (Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1930;
In the 1L, EXTREME regimen (Cetuximab + Cisplatin or Carboplatin + 5-Fluorouracil) was administered to 38%, 41% received other platinum-based therapy with/without a taxane, 11% received nivolumab as a single agent, 9% received other cetuximab-based therapy, and 1% received pembrolizumab. Between 2017 and 2018, platinum-based regimens including EXTREME continued to be the mainstay of 1L R/M SCCHN in these countries, with immunotherapy having high uptake in 2L.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Study of the Acquisition of Sensitivity to Paclitaxel Plus Cetuximab by the Addition of Low-dose Proteasome Inhibitor. (Pubmed Central) - Aug 31, 2022
The 'HOT' score is a simple and robust approach to identify real-world patients with HNSCC and NSCLC immunologically active tumours who may benefit from PD-1/PD-L1 inhibitors. Increased NF-B expression strongly contributes to resistance to paclitaxel-cetuximab, suggesting that the administration of small doses of bortezomib, which inhibits NF-B, combined with paclitaxel-cetuximab may enhance antitumor efficacy against cancer cells with low sensitivity to the combination therapy.
- |||||||||| Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial completion date, Metastases: ANCHOR-CRC: Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (clinicaltrials.gov) - Aug 30, 2022
P2, N=95, Active, not recruiting,
Initiation date: Dec 2021 --> Aug 2022 Trial completion date: Dec 2021 --> Oct 2022
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Journal: Optimal Light Dose for hEGFR-Targeted Near-Infrared Photoimmunotherapy. (Pubmed Central) - Aug 27, 2022
In this study, we show that a relatively low dose of NIR light is sufficient in an immunocompetent mouse model and avoids side effects seen with higher light doses required in immunocompetent mice. Thus, light dosing can be optimized in NIR-PIT based on the expected immune response.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, Visudyne (verteporfin) / Novartis
Journal: Remediating Desmoplasia with EGFR-Targeted Photoactivable Multi-Inhibitor Liposomes Doubles Overall Survival in Pancreatic Cancer. (Pubmed Central) - Aug 27, 2022
TPMILs targeted with cetuximab (anti-EGFR mAb) contain lipidated benzoporphyrin derivative (BPD-PC) photosensitizer and irinotecan...TPMIL photoactivation is also sixfold more effective at inhibiting tumor growth than a cocktail of Visudyne-photodynamic therapy (PDT) and nal-IRI, and also doubles survival and extends progression-free survival by greater than fivefold...Collagen nonalignment correlates with a reduction in tumor burden and survival. This single-construct phototoxic, chemotherapeutic, and desmoplasia-remediating regimen offers unprecedented opportunities to substantially extend survival in patients with otherwise dismal prognoses.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Erbitux! (Twitter) - Aug 26, 2022
- |||||||||| Biomarker, Review, Journal, PD(L)-1 Biomarker, IO biomarker: Colon Cancer Pharmacogenetics: A Narrative Review. (Pubmed Central) - Aug 26, 2022
Other treatments include biological therapies and immunotherapy with drugs such as bevacizumab, panitumumab, cetuximab, and pembrolizumab...Some other mutations in the thymidylate synthase gene (TSYM), methylenetetrahydrofolate reductase gene (MTHFR), and ATP binding cassette transporter B (ABCB1 and ABCB2) affect efficacy and security of the treatments. It is important to address the clinical implication of the oncologist in the study of gene mutations than can influence in the antitumoral response and safety of colon cancer treatments.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
P2 data, Journal: Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer. (Pubmed Central) - Aug 24, 2022
Promising results were observed with 3 out of 7 subjects demonstrating durable stable disease. These survival rates compare favourably with published data, thus justifying further development of cetuximab-based induction chemoradiotherapy.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Screening and Identification of A Novel Anti-Siglec-15 Human Antibody 3F1 and Relevant Antitumor Activity. (Pubmed Central) - Aug 24, 2022
In the tumor model of Balb/c Nude mice, 3F1 (10 mg/kg) showed certain antitumor effects [tumor growth inhibition (TGI) was 31.5%], while the combination of 3F1 (5 mg/kg) and Erbitux (5 mg/kg) showed significant antitumor effects (TGI was 48.7%) compared with the PBS group...In conclusion, novel human antibody 3F1 has anti-tumor activity and is expected to be an innovative candidate drug targeting siglec-15 for tumor immunotherapy Significance Statement Siglec-15 is considered as an important target in the next generation of tumor immunotherapy. 3F1 is expected to be the most promising potential candidate for targeting siglec-15 for cancer treatment, and could provide a reference for the development of anti-tumor drugs.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date: INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy (clinicaltrials.gov) - Aug 24, 2022
P2, N=67, Active, not recruiting,
However, there was no significant difference in OS in left-sided mCRC. Trial completion date: Jul 2022 --> Nov 2023 | Trial primary completion date: Jul 2022 --> Nov 2022
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Journal: BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape. (Pubmed Central) - Aug 22, 2022
Treatment regimens currently under exploration in BRAF-mutant metastatic colorectal cancer include combinatorial options of various pathway-targeted therapies, cytotoxic chemotherapy, and/or immune checkpoint blockade, among others. Circumvention of adaptive and acquired resistance to BRAF-targeted therapies is a significant challenge to be overcome in BRAF-mutated advanced colorectal cancer.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
New P2 trial: NeoBRAF: Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer (clinicaltrials.gov) - Aug 22, 2022
P2, N=48, Not yet recruiting,
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Retrospective data, Review, Journal, Adverse events, Serious adverse event: Safety Assessment on Serious Adverse Events of Targeted Therapeutic Agents Prescribed for RAS Wild-Type Metastatic Colorectal Cancer: Systematic Review and Network Meta-Analysis. (Pubmed Central) - Aug 22, 2022
Although both cetuximab and panitumumab demonstrated increased risk of serious dermatological and renal toxicities, panitumumab-based chemotherapy has relatively higher risk of skin toxicity (RR 15.22; 95% CI 7.17-32.35), mucositis (RR 3.18; 95% CI 1.52-6.65), hypomagnesemia (RR 20.10; 95% CI 5.92-68.21), and dehydration (RR 2.81; 95% CI 1.03-7.67) than cetuximab-based chemotherapy. Thus, further studies on risk stratification and SAE management are warranted for safe administration of targeted agents.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Advances in nuclear medicine-based molecular imaging in head and neck squamous cell carcinoma. (Pubmed Central) - Aug 22, 2022
However, targeted therapy, e.g., cetuximab, an epidermal growth factor receptor inhibitor, has demonstrated survival benefit in HNSCC patients with locoregional failure or distant metastasis...The preclinical and clinical applications of these candidate imaging strategies are divided into three categories: those targeting tumor cells, tumor microenvironment, and tumor angiogenesis. This review endeavors to expand the knowledge of molecular biology of HNSCC and help realizing diagnostic potential of molecular imaging in clinical nuclear medicine.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: PembroRad: Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC (clinicaltrials.gov) - Aug 19, 2022
P2, N=133, Active, not recruiting,
This review endeavors to expand the knowledge of molecular biology of HNSCC and help realizing diagnostic potential of molecular imaging in clinical nuclear medicine. Trial completion date: Dec 2021 --> Oct 2023 | Trial primary completion date: Aug 2021 --> Oct 2022
|
